The first biosimilars referencing Humira became available in 2023. That year, 10 FDA-approved adalimumab are now on the ...
The US Food and Drug Administration (FDA) on Friday announced it had approved Amgen's Amjevita (adalimumab-atto), the first biosimilar version of AbbVie's best-selling biologic Humira (adalimumab). In ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results